Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
- Conditions
- Malignant Melanoma
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Mt. Sinai Medical Center, Miami
- Target Recruit Count
- 36
- Registration Number
- NCT00616564
- Locations
- 🇺🇸
Jose Lutzky, MD, Miami Beach, Florida, United States
🇺🇸David Lawson, MD, Atlanta, Georgia, United States
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- Biological: therapeutic autologous lymphocytesGenetic: Use of an artificial antigen presenting cell (aAPC) to generate CTLDrug: GM-CSFRadiation: Irradiation of cutaneous tumor lesion
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-03-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00512889
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: Campath-1HDrug: G-CSFDrug: GM-CSFDrug: BCNUDrug: Stem Cell TransplantDrug: Preparative Regimen for Allogenic Stem Cell TransplantationDrug: CytarabineDrug: EtoposideDrug: MelphalanDrug: CampathDrug: FludarabineDrug: CyclophosphamideRadiation: Low dose total body irradiation
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00505921
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 84
- Registration Number
- NCT00499343
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00477087
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Diffuse
- Interventions
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT00455897
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00450008
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00448409
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00447473
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00446173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.